/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Debates & Insight
QuintilesIMS Rare Diseases webinar _16x9 holding slide_170405
Sponsored

When small becomes big: orphan medicines, advances, access a...

Significant unmet need still remains in the rare disease market, only around 5% of rare diseases currently have an approved drug treatment. This represents a major opportunity for the pharmaceutical industry. Our webinar will assess the critical factors underpinning success in the rare disease space and provide a view into the future of market access and health technology assessments for orphan medicines – alongside the impact on R&D and clinical trials – in the context of Brexit negotiations.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Oncology
Print
Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Patients

R&D

Digital